The BioNJ Diagnostics and Precision Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, the government and investors in the State of New Jersey.
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.
To advance the development of Diagnostics & Precision Medicine (DxPM) in New Jersey by identifying and support partnerships with industry, academia, government and investors in the State, advocating for local and national policy changes that creates a positive environment for DxPM innovation, and by providing ongoing education and support for DxPM participants.
A highly networked ecosystem and platform for participants in the field of Diagnostics and Precision Medicine to collectively leverage knowledge, experience and opportunity for the advancement of better individualized patient outcomes and value.
Peter Hoehn, Global Business Leader, Janssen Diagnostics
Panna Sharma, President & CEO, Cancer Genetics, Inc.
Nigel Russell, The Journal of Precision Medicine
Vincent A. Smeraglia, Executive Director, Office of Research Commercialization, Rutgers, The State University of New Jersey
Peter Tolias, Ph.D., Professor and Director, Center for Healthcare Innovation, Center for Healthcare Innovation, Stevens Institute
John Kouten, CEO, JFK Communications, Inc.
Joe Montemarano, MIRTHE Executive Director, Princeton University
Lieven Nuyttens, Principal, Tri-Medix, LLC
Zeil Rosenberg, Vice President, Medical Affairs, Admera Health
To stay informed of BioNJ’s Diagnostics and Precision Medicine activities and events, please complete the following information.
If you are interested in becoming a sponsor of the BioNJ Diagnostics and Precision Medicine
Committee, please contact BioNJ at BioNJ@BioNJ.org or by phone at 609-890-3185.